XBIO
Xenetic Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+0.86%Year over year
Reported trailing growth
- Revenue
- +33.3%
- EBITDA
- +22.4%
- EBIT
- +19.1%
- EPS
- +40.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +20.4%
- EBITDA
- +29.6%
- EBIT
- +32.6%
- Net income
- +32.3%
- EPS
- +38.5%
- Free cash flow
- +18.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026